# Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

> **NCT02328963** · PHASE4 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 186 (actual)

## Conditions studied

- Transplantation Infection
- Cytomegalovirus Infection

## Interventions

- **DRUG:** Everolimus
- **DRUG:** mycophenolic acid

## Key facts

- **NCT ID:** NCT02328963
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-02
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-10-10
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2018-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328963, "Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02328963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*